CURE SYNGAP1 has launched an Economic and Humanistic Burden Study designed to quantify how SYNGAP1-Related Disorders affect patients, caregivers and families beyond the information captured by conventional clinical measures. The planned U.S. study is expected to include at least 125 caregivers, with families helping to develop and test the survey instrument, and will examine quality of life, caregiving, independence, education, employment and family finances. It is the first major evidence initiative under REACH SYNGAP1, a community-driven, precompetitive program led by the nonprofit organization in partnership with Global Genes, Kielo Research and Citizen Health.
The announcement comes as potential treatments for SYNGAP1-Related Disorders, or SRD, move toward clinical development. The study will not test a therapy or establish its effectiveness. Instead, it is intended to build an evidence base for future discussions involving regulators, payers, policymakers, therapy developers and patient advocates about the full effects of the disorder and the changes that patients and families would consider meaningful. The partners say this information is needed earlier in the development process, when treatment and coverage decisions are being shaped, rather than after a therapy reaches the market.
Global Genes will lead the effort, including survey development, family engagement and data collection through its RARE-X research platform. Kielo Research, a Sanius Health company, will contribute health economics expertise to the survey methodology and statistical analysis. Citizen Health will support the project through its work with CURE SYNGAP1’s retrospective natural history study. The partnership also builds on CURE SYNGAP1’s existing use of RARE-X for the prospective SYNGAP1 ProMMiS natural history study, creating a way to connect families already participating in different research activities with the new burden study.
The questionnaire will be adapted from a caregiver burden survey developed for Angelman syndrome, with modifications intended to reflect the experiences and priorities of the SYNGAP1 community. CURE SYNGAP1 reports that more than half of its known U.S. population is already enrolled across the RARE-X and Citizen Health platforms. Although this existing participation may support recruitment, the announcement does not provide a final response rate, recruitment timeline or statistical power calculation. The at-least-125 caregiver figure therefore describes the planned U.S. sample rather than a completed cohort or a demonstrated finding.
SYNGAP1-Related Disorders are rare genetic conditions caused by variants in the SYNGAP1 gene that reduce levels of SYNGAP1 protein. The protein regulates synapses, the specialized junctions through which neurons communicate. When its levels are too low, increased excitability can interfere with effective neuronal signaling and contribute to neurological impairment. Reported features include autism spectrum disorder, global developmental delay leading to intellectual disability, epilepsy, hypotonia, gross and fine motor delays, visual abnormalities such as strabismus, disordered sleep and gastrointestinal challenges. CURE SYNGAP1 says it has identified more than 1,871 people with SRD to date.
The planned analysis goes beyond a conventional account of diagnosis, seizure frequency or other clinical outcomes. It will assess domains that may shape daily life and the resources required to support a person with SRD, including caregiver burden, functional independence, opportunities in education and employment, household finances and quality of life. Kielo’s stated role includes translating these domains into methods that can support health-economic analysis and regulatory, payer and health-technology assessment submissions. The study is therefore intended to produce observational evidence about disease burden, not causal estimates of the disorder’s effects or forecasts of treatment benefit.
CURE SYNGAP1 President and Chief Operating Officer Virginie McNamar said the disorder affects many parts of a patient’s and family’s life, including seizures, communication, sleep and independence. The organization’s aim, she said, is to document the consequences that families experience in order to make clear what meaningful improvement could mean as treatments advance. Founder and Chief Executive Officer Mike Graglia described the collaboration as a way to build real-world evidence from an existing community network and argued that such evidence is important for advocacy on behalf of SYNGAP1 families.
Global Genes Senior Director of Scientific Programs Karmen Trzupek said the broader impact includes caregivers’ mental health, family stability and household finances, areas that may not be apparent during a clinical encounter. She said evidence of this kind must be available before a new medicine reaches the market if it is to inform coverage decisions and reduce potential delays. The study is precompetitive: the announcement describes it as an evidence initiative intended for broad use across the scientific, regulatory and patient-advocacy communities, rather than as a project commissioned for one sponsor’s proprietary program.
Expected outputs include a comprehensive report, a peer-reviewed manuscript, a scientific conference abstract and a poster. The partners have not yet reported results, estimates of economic cost, longitudinal changes or comparisons with other neurodevelopmental disorders. The announcement also gives no completion date for data collection and does not specify the survey’s full instrument, scoring methods, eligibility criteria or analysis plan. Those elements will be needed to assess how the evidence is collected, which outcomes are most robust, and how broadly any estimates can be applied.
The project sits within REACH, which expands to Regulatory, Evidence, Access, Community Empowerment and Health Policy. Its stated workstreams include patient-informed regulatory engagement, evidence on disease burden and meaningful outcomes, preparation for future access and reimbursement needs, family advocacy and health policy. Current priorities also include a Patient Listening Session with the U.S. Food and Drug Administration scheduled for April 2027. Together, the study and listening session reflect an effort to incorporate lived experience into the infrastructure surrounding therapy development, although the survey’s findings will depend on the forthcoming data and will not by themselves demonstrate that any intervention improves those outcomes.
Subject of Research: Planned real-world evidence study of the economic and humanistic burden of SYNGAP1-Related Disorders
Article Title: CURE SYNGAP1 partners with Global Genes, Kielo Research and Citizen Health to launch economic and humanistic burden study
Article References: CURE SYNGAP1 partners with Global Genes, Kielo Research and Citizen Health to launch economic and humanistic burden study. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: SYNGAP1, rare diseases, caregiver burden, health economics, patient-reported outcomes, real-world evidence, neurodevelopmental disorders, quality of life, CURE, partners, Global, Genes
